
Last updated: 2026-09-09 05:05:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Aclaris Therapeutics, Inc. (ACRS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $6,06, with a market capitalization of $908,22M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,74 to $6,60. This page covers its latest market performance, valuation, price trends and company information.
$908,22M | |
$6,08 | |
$33,88 | |
$0,59 | |
$6,17 | |
2,82M | |
1,90M | |
-- | |
$6,60 | |
$1,74 | |
-- | |
-- |
Aclaris Therapeutics, Inc. (ACRS) last closed at $6,17 as of 2026-09-08 23:31:00, unchanged from the previous close of $6,17.
During the latest regular trading session, ACRS traded between $0,59 and $33,88, with a volume of 2,82M shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Aclaris Therapeutics, Inc. (ACRS) moved from $6,16 to $6,06, representing a decline of 1,70% ($0,11).
The stock traded between $5,73 and $6,31 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 1,49 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 88,8%
ACRS is currently trading at $6,06, placing it 88,8% of the way from its 52-week low of $1,74 to its 52-week high of $6,60. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 73 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Aclaris Therapeutics, Inc. (ACRS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.